Sign In
Buy BXRX
$0.0218
+0 (+0%)
At Close: May 28, 2024
Baudax Bio Shares Increase Over 45% Pre-Market: Why It Happened
06:59am, Tuesday, 24'th Aug 2021
The shares of Baudax Bio Inc (NASDAQ: BXRX) increased by over 45% pre-market. This is why it happened.
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q2 2021 Results - Earnings Call Transcript
03:10am, Sunday, 08'th Aug 2021
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q2 2021 Results - Earnings Call Transcript
Baudax Bio: Q2 Earnings Insights
08:05am, Thursday, 05'th Aug 2021
Shares of Baudax Bio (NASDAQ:BXRX) rose 0.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 87.79% year over year to ($0.21), which missed th
Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights
07:00am, Thursday, 05'th Aug 2021
Total Number of ANJESO ® Vials Sold to End-Users in the Second Quarter 2021 Match Total Vials Sold for the Full Year 2020
Baudax Bio Announces Date of Reconvened Special Meeting
04:05pm, Friday, 30'th Jul 2021
Special Meeting to be reconvened on August 11, 2021 solely with respect to Proposal 1 Special Meeting to be reconvened on August 11, 2021 solely with respect to Proposal 1
MALVERN, Pa., July 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today ann
MALVERN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today an
Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock
04:05pm, Friday, 18'th Jun 2021
Special meeting to be held virtually on July 13, 2021, at 9:00 a.m. Eastern Time Special meeting to be held virtually on July 13, 2021, at 9:00 a.m. Eastern Time
Baudax Bio's ANJESO® Achieves Formulary Listing at Over 100 Institutions in Less Than One Year on the Market
07:00am, Tuesday, 08'th Jun 2021
MALVERN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today an
Baudax Bio Announces $11.9 Million Registered Direct Offering
10:56pm, Monday, 31'st May 2021
MALVERN, Pa., May 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today ann
Baudax Bio Announces the Cancellation of Adjourned Portion of Annual Shareholder Meeting
04:05pm, Friday, 28'th May 2021
MALVERN, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care
MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care
Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote "For" The Additional Authorized Shares
09:02am, Wednesday, 12'th May 2021
MALVERN, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q1 2021 Results - Earnings Call Transcript
12:33pm, Wednesday, 05'th May 2021
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q1 2021 Results - Earnings Call Transcript
Baudax Bio's Preoperative Med Associated With Pain Reduction, Lower Opioids Use In Patients After Knee Replacement
10:05am, Monday, 26'th Apr 2021
Baudax Bio Inc (NASDAQ: BXRX) has announced the online publication of Phase 3b study data highlighting the safety and efficacy of preoperative Anjeso (meloxicam) injection in patients undergoing u
